Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$2.51 - $5.25 $381 - $798
-152 Reduced 46.34%
176 $0
Q4 2022

Feb 14, 2023

SELL
$1.65 - $2.35 $165 - $235
-100 Reduced 23.36%
328 $0
Q3 2022

Nov 14, 2022

SELL
$1.84 - $2.79 $2,208 - $3,348
-1,200 Reduced 73.71%
428 $1,000
Q2 2022

Oct 27, 2022

SELL
$1.52 - $2.99 $3,380 - $6,649
-2,224 Reduced 57.74%
1,628 $3,000
Q2 2022

Aug 15, 2022

SELL
$1.52 - $2.99 $3,380 - $6,649
-2,224 Reduced 57.74%
1,628 $3,000
Q1 2022

Oct 27, 2022

BUY
$2.87 - $4.9 $6,382 - $10,897
2,224 Added 136.61%
3,852 $11,000
Q1 2022

May 13, 2022

BUY
$2.87 - $4.9 $11,055 - $18,874
3,852 New
3,852 $11,000

Others Institutions Holding RNXT

About RenovoRx, Inc.


  • Ticker RNXT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,066,860
  • Market Cap $9.25M
  • Description
  • RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...
More about RNXT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.